낮은 역가 MOG항체 양성 소견의 신중한 해석과 감별 진단의 중요성
- 현재원, 김호진
The Importance of Cautious Interpretation and Differential Diagnosis in Low-Titer MOG Antibody Positivity
- Jae-Won Hyun, MD, PhD, Ho Jin Kim, MD, PhD
- Received February 17, 2025 Accepted March 12, 2025
- NOTES
- NOTES
-
Acknowledgements None.
Author Contributions Conceptualization: JWH. Writing - review & editing: JWH and HJK. Supervision: HJK.
Conflicts of Interest JWH has received a grant from the National Cancer Center in Korea. HJK received a grant from the National Research Foundation of Korea and research support from Aprilbio and Eisai; received consultancy/speaker fees from Alexion, Aprilbio, Altos Biologics, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, Handok, Horizon Therapeutics, Kaigene, Kolon Life Science, MDimune, Mitsubishi Tanabe Pharma, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, and UCB. HJK is a co-editor for the Multiple Sclerosis Journal and an associated editor for the Journal of Clinical Neurology.
Funding Statement None.
Data Availability Statement Not applicable.
Ethical Approval Not applicable.
Patient Consent for Publication Not applicable.
- REFERENCES
- REFERENCES
- 1. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol 2023;22:268-282.
[Article] [PubMed]2. Budhram A, Flanagan EP. Testing for myelin oligodendrocyte glycoprotein antibodies: who, what, where, when, why, and how. Mult Scler 2025;31:505-511.
[Article] [PubMed] [PMC]3. Kim JS. Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as a diffuse pachymeningitis. J Mult Scler Neuroimmunol 2024;15:85-86.
[Article]